Characterization of the heart rate-lowering action of ivabradine, a selective If current inhibitor

American Journal of Therapeutics

Volumn 15, Issue 5, 2008, Pages 461-473

  Borer, Jeffrey S ^a,c   Le Heuzey, Jean Yves ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c NONE   (United States)

Author keywords

Heart rate; Ischemia; Ivabradine; Sinoatrial node; Stable angina

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ISOPRENALINE; ISOSORBIDE 5 NITRATE; IVABRADINE; KETOCONAZOLE; LERCANIDIPINE; NIFEDIPINE; ORGANIC NITRATE; PLACEBO; PROPRANOLOL; VERAPAMIL; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CYCLIC NUCLEOTIDE GATED CHANNEL;

ARTERIAL PRESSURE; BRADYCARDIA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; HEART DEPOLARIZATION; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOTENSION; INOTROPISM; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS NODE; STABLE ANGINA PECTORIS; TACHYCARDIA; ANGINA PECTORIS; BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; HEART RATE; PATHOPHYSIOLOGY; TIME;

ANGINA PECTORIS; BENZAZEPINES; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HEART RATE; HUMANS; TIME FACTORS;

EID: 55249085851     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181758855     Document Type: Review

References (79)

1. (f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817-823.
2. (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529-2536.
3. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393-405.
4. Fox K, Garcia MA, Ardessino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381.
5. Panza JA, Diodati JG, Callahan TS, et al. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischaemia during daily life in patients with coronary artery disease. J Am Coll Cardiol. 1992;20:1092-1098.
6. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to antiischemic medication. Circulation. 1993;88:92-100.
7. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers: the Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J. 2004;25:1341-1362.
8. Guth BD, Heusch G, Seitelberger R, et al. Mechanism of benefit of β-adrenergic blockade on exercise-induced myocardial ischaemia in conscious dogs. Circ Res. 1987;60:738-746.
9. Simonsen S, Ihlen H, Kjekshus JK. Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand. 1983;213:393-398.
10. 2+ release contributes to automaticity in cat atrial pacemaker cells. J Physiol. 2000;524:415-422.
11. Bucchi A, Baruscotti M, Robinson RB, et al. Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J Mol Cell Cardiol. 2007;43:39-48.
12. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol. 1993;55:451-467.
13. DiFrancesco D. Dual allosteric modulation of pacemaker (f) channels by cAMP and voltage in rabbit SA node. J Physiol. 1999;515:367-376.
14. DiFrancesco D. Serious workings of the funny current. Prog Biophys Mol Biol. 2006;90:13-25.
15. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature. 1979;280:235-236.
16. f) induced by acetylcholine in rabbit sino-atrial node myocytes. J Physiol. 1988;405:477-491.
17. f) in rabbit sino-atrial node myocytes. J Physiol. 1988;405:493-510.
18. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399-406.
19. f channels by ivabradine. J Gen Physiol. 2002;120:1-13.
20. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757-1765.
21. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37-42.
22. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol. 1997;339:43-51.
23. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051-1057.
24. f current inhibitor ivabradine: a new therapeutic approach to ischaemic heart disease. Pharmacol Res. 2006;53:424-434.
25. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83-89.
26. (f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149-155.
27. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61:127-137.
28. f current inhibition by ivabradine and cardiac pacemaking activity [abstract]. Eur Heart J. 2006;27(Suppl):380.
29. Wilders R, Jongsma HJ, van Ginneken AC. Pacemaker activity of the rabbit sinoatrial node. A comparison of mathematical models. Biophys J. 1991;60:1202-1216.
30. Noble D, Bert G. Reconstructing the heart: a challenge of integrative physiology. Cardiovasc Res. 1993;27:1701-1712.
31. f. J Physiol. 1990;429:401-409.
32. Shi W, Wymore R, Yu H, et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res. 1999;85:e1-e6.
33. Moosmang S, Stieber J, Zong X, et al. Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem. 2001;268:1646-1652.
34. (f) in adult canine cardiac ventricular myocytes. J Physiol. 1995;485:469-483.
35. Bucchi A, Tognati R, Milanesi M, et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572:335-346.
36. Gardiner SM, Kemp PA, March JE, et al. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115:579-586.
37. Thollon C, Bedut S, Villeneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150:37-46.
38. (f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol. 2004;142:107-112.
39. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666.
40. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004,109:1674-1679.
41. Newton CR, Delgado JH, Gomez HF. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. Semin Respir Crit Care Med. 2002;23:19-25.
42. Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63:1828-1835.
43. DeWitt CR, Waksman JC. Pharmacology, pathophysiology, and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23:223-238.
44. Love JN, Litovitz TL, Howell JM, et al. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. Toxicol Clin Toxicol. 1997;35:353-359.
45. Vliegen HW, van der Wall EE, Niemeyer MG, et al. Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18(Suppl 9):S55-S60.
46. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531.
47. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation. 2002;106:2510-2513.
48. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest. 2004;113:352-354.
49. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
50. Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482-489.
51. (f) inhibitor ivabradine on pretreatment resting heart rate. Eur Heart J. 2007;28(Suppl):321. Abstract P1991.
52. f current inhibitor ivabradine: heart rate reduction depends on baseline heart rate [Abstract 1007]. J Am Coll Cardiol. 2007;49(Suppl 1):195.
53. Boden WE, Vray M, Eschwege E, et al. Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. Clin Cardiol. 2001;24:73-79.
54. Diaz A, Bourassa MG, Guertin M-C, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967-974.
55. Jouven X, Empana J-P, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951-1958.
56. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26:637-644.
57. Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-1494.
58. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F-32F.
59. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J. 1988;116:515-523.
60. Miller RR, Olson HG, Amsterdam EA, et al. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975;293:416-418.
61. Brynne L, Paalzow LK, Karlsson MO. Mechanism-based modelling of rebound tachycardia after chronic L-propranolol infusion in spontaneous hypertensive rats. J Pharmacol Exp Ther. 1999;290:664-671.
62. Nattel S, Rangno RE, Van Loon G. Mechanisms of propranolol withdrawal phenomena. Circulation. 1979;59:1158-1164.
63. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol. 1988;61:1219-1222.
64. Rangno RE, Langlois S, Lutterodt A. Metoprolol withdrawal phenomena: mechanism and prevention. Clin Pharmacol Ther. 1982;31:8-15.
65. Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990;263:1653-1657.
66. Camm AJ, Le Heuzey J-Y, Jem S, et al. Heart rate variability is significantly increased by ivabradine compared with amlodipine in patients with chronic stable angina: a prospective randomised double-blind controlled study [Abstract 908]. J Am Coll Cardiol. 2007;49(Suppl 1):242.
67. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043-1065.
68. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol. 2005;10:88-101.
69. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90:878-883.
70. Wennerblom B, Lurje L, Tygesen H, et al. Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone. Heart. 2000;83:290-294.
71. Forslund L, Bjorkander I, Ericson M, et al. Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. Heart. 2002;87:415-422.
72. van Boven AJ, Jukema JW, Haaksma J, et al. Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. REGRESS Study Group. Am Heart J. 1998;135:571-576.
73. Wennerblom B, Lurje L, Westberg S, et al. Effects on heart rate variability of isosorbide-5-mononitrate and metoprolol in patients with recent onset of angina pectoris. Cardiology. 1998;89:87-93.
74. Weber F, Schneider H, von Arnim T, et al. Heart rate variability and ischemia in patients with coronary heart disease and stable angina pectoris: influence of drug therapy and prognostic value. Total Ischemic Burden Bisoprolol Study. Eur Heart J. 1999;20:38-50.
75. Lampert R, Ickovics JR, Viscoli CJ, et al. Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial. Am J Cardiol. 2003;91:137-142.
76. Chern CM, Hsu HY, Hu HH, et al. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. J Cardiovasc Pharmacol. 2006;47:169-174.
77. Acanfora D, Trojano L, Gheorghiade M, et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther. 2002;9:444-453.
78. Stein PK, Kleiger RE. Insights from the study of heart rate variability. Annu Rev Med. 1999;50:249-261.
79. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effect of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42:688-696.